Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gefitinib trial in a fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma.

Literature DB >> 19956375

Gefitinib trial in a fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma.

Hae Sun Jung¹, Gun-Woo Byun, Kyoung-Eun Lee, Yeung Chul Mun, Seung Hyun Nam, Jung Mi Kwon, Shi Nae Lee, Seock-Ah Im, Chu-Myong Seong, Soon Nam Lee.

Abstract

FA (Fanconi's Anemia) is an autosomal recessive disorder that is characterized by pancytopenia with bone marrow hypoplasia, diverse congenital abnormalities and an increased predisposition towards malignancy. The mainstay of the treatment for these cancers has been surgery, because of the hypersensitive reactions of FA patients to DNA cross- linking agents or radiation. Therefore, there has been no effective therapy for advanced squamous cell carcinoma. We report here on a patient suffering from advanced multiple squamous cell carcinoma and hepatocellular carcinoma along with an FA, and this patient was treated with gefitinib.

Entities: Chemical Disease Species

Keywords: Fanconi's anemia; Gefitinib; Squamous cell carcinoma

Year: 2005 PMID： 19956375 PMCID： PMC2785935 DOI： 10.4143/crt.2005.37.6.370

Source DB: PubMed Journal: Cancer Res Treat ISSN： 1598-2998 Impact factor: 4.679

14 in total

1. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

Authors: Nicola Normanno; Massimo Di Maio; Francesco Perrone; Manuela Campiglio
Journal: J Clin Oncol Date: 2004-05-15 Impact factor: 44.544

2. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

Authors: Fred R Hirsch; Marileila Varella-Garcia; Jason McCoy; Howard West; Ana Carolina Xavier; Paul Gumerlock; Paul A Bunn; Wilbur A Franklin; John Crowley; David R Gandara
Journal: J Clin Oncol Date: 2005-07-05 Impact factor: 44.544

3. Investigation of HER2 overexpression in non-small cell lung cancer.

Authors: Katalin Ugocsai; László Mándoky; László Tiszlavicz; Joseph Molnár
Journal: Anticancer Res Date: 2005 Jul-Aug Impact factor: 2.480

4. Androgenic steroids and hepatocellular carcinoma.

Authors: J T Guy; M O Auslander
Journal: Lancet Date: 1973-01-20 Impact factor: 79.321

5. Familial hypoplastic anemia with multiple congenital anomalies (Fanconi's syndrome)--report of three cases. Cases presented are of two sisters and a female cousin with complete clinical and post mortem findings.

Authors: A Esparza; W R Thompson
Journal: R I Med J Date: 1966-02

Review 6. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.

Authors: Roy S Herbst
Journal: Expert Opin Investig Drugs Date: 2002-06 Impact factor: 6.206

7. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.

Authors: Hu Xu; Yingjie Yu; Dorota Marciniak; Arun K Rishi; Fazlul H Sarkar; Omer Kucuk; Adhip P N Majumdar
Journal: Mol Cancer Ther Date: 2005-03 Impact factor: 6.261

8. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

Authors: Federico Cappuzzo; Marileila Varella-Garcia; Hisayuki Shigematsu; Irene Domenichini; Stefania Bartolini; Giovanni L Ceresoli; Elisa Rossi; Vienna Ludovini; Vanesa Gregorc; Luca Toschi; Wilbur A Franklin; Lucio Crino; Adi F Gazdar; Paul A Bunn; Fred R Hirsch
Journal: J Clin Oncol Date: 2005-08-01 Impact factor: 44.544

Gefitinib trial in a fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma.

1. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

2. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

3. Investigation of HER2 overexpression in non-small cell lung cancer.

4. Androgenic steroids and hepatocellular carcinoma.

5. Familial hypoplastic anemia with multiple congenital anomalies (Fanconi's syndrome)--report of three cases. Cases presented are of two sisters and a female cousin with complete clinical and post mortem findings.

Review 6. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.

7. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.

8. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

9. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

Review 10. Head and neck carcinoma in Fanconi's anaemia--report of a case and review of the literature.

1. Oral Tongue Cancer in a Patient with Fanconi Anemia: A Case Report and Literature Review.

2. Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.